Introduction
Erythropoietic protoporphyria (EPP) is an inherited disease which may result when there is a defect in one or both of the alleles of the gene coding for ferrochelatase (protoheme ferrolyase, E.C. 4 .99.1.1), the terminal enzyme in the heme synthetic pathway that catalyzes the insertion of ferrous iron into protoporphyrin IX to form protoheme IX (heme) [1] [2] [3] [4] . The most common clinical symptom of the disease is a painful dermatological photosensitivity that is attributable to accumulation of protoporphyrin IX in the skin and the subsequent generation of tissue-damaging free radicals upon exposure to visible light. While the disease is generally categorized as a mild photosensitivity, in approximately 5% of cases the excess protoporphyrin drastically affects the solubility of bile, leading to the formation of gallstones and eventually marked cholestasis which may result in cirrhosis and liver failure 5, 6 . Although the gene defect results in lowered ferrochelatase activity in all tissues, it is in the erythrocyte precursors in bone marrow where quantitatively the largest amount of protoporphyrin is produced. Given the fact that the progenies of these cells contain the largest amount of organismal heme and have relatively short life spans, it is apparent how EPP is an erythroid rather than hepatic porphyria. Ferrochelatase activities in the livers and kidneys of EPP patients are diminished, but it is only under special conditions where there may be an impact on the metabolic function of the liver 5, 6 . Indeed, even in EPP patients where liver cirrhosis necessitates transplantation, the damage is caused by biliary occlusion composed of free protoporphyrin crystals that come from circulating erythrocytes and not produced by the liver itself. This results in the unfortunate sequelae of potential repeat liver transplants only.
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Although EPP is primarily an autosomal dominantly inherited disease with only one mutant ferrochelatase allele found in affected patients, a few homozygous, recessive patients have been reported 7, 8 . Interestingly in vivo residual ferrochelatase activity in patients is only 10-30% of normal. Individuals with 50% residual activity are usually not symptomatic. Over the past two decades, several hypotheses have been forwarded to explain this observation including a three allele, autosomal resessive hypothesis 9, 10 .
Currently available data support a model where clinical EPP and the 10-30% residual ferrochelatase activity result when an individual possesses an EPP mutant allele along with one wild type allele that is a low expression allele. Thus, decreased activity results from a diminished synthesis of normal ferrochelatase mRNA along with a normal level of EPP transcript. This low expression allele is associated with a -251G/IVS1-23T marker 11, 12 . While there are good data supporting this model for many published clinical EPPs, there are additional possibilities to be considered for some other EPPs.
One hypothesis raised previously and considered below is based upon the homodimeric structure of human ferrochelatase 13, 14 . The crystal structure of human ferrochelatase reveals that the enzyme is a homodimeric protein with a dimeric molecular weight of 86,000 and that it contains one [2Fe-2S] cluster per monomeric subunit 13 . The nuclear-encoded and cytoplasmically synthesized precursor of the enzyme is translocated, proteolytically processed and bound to the matrix side of the inner mitochondrial membrane 1, 15, 16 . Assuming an equivalent level of transcription and translation of both normal and EPP ferrochelatase alleles, it would be expected that the ratio of homodimeric 
Materials and Methods

Construction of heterodimeric mutant human ferrochelatase expression vectors
only.
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The production of heterodimeric mutant human ferrochelatase (enzyme containing one normal and one mutant subunit) was accomplished using two ferrochelatase expression vectors. One vector, pHisTF20E, contains a 6-histidine-tag and an ampicillin resistance gene along with a ferrochelatase cDNA containing an EPP mutation under control of the Tac (Roche) promoter. The construction of this vector has been described previously 14 . The second vector was designed to contain the wild type ferrochelatase cDNA under the control of the TrcHis promoter (Invitrogen, Carlsbad, CA) with a CBP-tag (calmodulin binding protein) and a kanamycin resistance gene. The vector was constructed in multiple steps from plasmid pTrcHisA (Invitrogen, Carlsbad, CA) by replacing the ampicillin resistance gene with the kanamycin resistance gene. The his-tag was replaced with a CBP-tag cassette that had been produced by PCR and then this vector was subjected to restriction digestion to insert the cDNA coding for human ferrochelatase R115L, a mutant which exhibits wild-type kinetics but is more stable than the wild-type enzyme as purified. The resulting plasmid was named pTrc-CBPkanamycin-human ferrochelatase. For simplicity the enzyme produced using this plasmid will be referred to as wild-type.
Construction of His-tag mutant human ferrochelatase (hFc)
To create different hFc mutations, the plasmid pHisTF20E containing the R115L mutation was used as the template in site directed mutagenesis. Site directed mutagenesis was performed using the QuikChange Site-Directed Mutagenesis kit (Stratagene, LaJolla, CA) with synthetic oligonucleotides containing the desired specific base changes corresponding to the EPP mutations investigated in this study. Mutated plasmids were only.
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Expression of His/CBP-tag and His-tag wild-type and mutant human ferrochelatases
Expression of recombinant human ferrochelatase was carried out in E.coli JM109 containing the appropriate antibiotic(s), either ampicillin (final concentration 0.1mg/ml), kanamycin (final concentration 0.2mg/ml), or both. Cultures were started by inoculating one colony containing His-tag, CBP-tag, or both into 100ml Circlegrow (QBiogene, Carlsbad, CA). Cultures were grown at 30ºC in 500 ml Pyrex R flasks with shaking at 225 rpm. After 6 hours, the 100 ml culture was transferred into one liter of Circlegrow containing the appropriate antibiotic(s) and cultures were grown at 30ºC for 18-20 hours in 2800 ml Fernbach flasks with shaking at 225 rpm. Wild type and mutant human ferrochelatase homodimers were purified as described previously 14 .
Purification of mutant heterodimeric human ferrochelatase
For the purification of expressed heterodimeric ferrochelatases all buffers, solutions, and purification steps were at 4ºC. Cells were harvested by centrifugation and the pellet was resuspended in 60 ml solubilization buffer (50 mM Tris-MOPS, pH 8.0, 0.1 M KCl, 1.0 % sodium cholate). Cells were sonicated and centrifuged as was described for the homodimers 14 
Characterization of homodimeric and heterodimeric human ferrochelatases
Characterization by UV-visible spectroscopy UV-visible spectroscopy was conducted using a Cary-G1 spectrophotometer.
Wild type and mutant ferrochelatase concentrations were determined using the extinction 
Kinetic analysis of wild type, homodimeric and heterodimeric mutant ferrochelatases
Ferrochelatase activity was assayed aerobically at room temperature by continuous spectrophotometric monitoring of the disappearance of the porphyrin substrate by following the decrease in the absorbance of the porphyrin substrate at 496 nm. The extinction coefficient of 7.5 mM -1 ·cm -1 was used to determine the amount of heme produced. Freshly prepared 10-100 µM ferrous ammonium sulfate and 10-100 µM mesoporphyrin IX (Frontier Scientific, Logan, UT) were used as substrates.
Mesoporphyrin stock solution was made by mixing 2.5 mg mesoporphyrin IX, 30 µl 2N
NH 4 OH, 500 µl 10% Triton X-100 in 4.5 ml double distilled water. Mesoporphyrin The ferrochelatase assay mixture contained in one ml 100 mM Tris-HCl (pH 8.0), 0.5% Tween 20, 1 mM mesoporphyrin, 1 mM ferrous ammonium sulfate and 10 mM β-mercaptoethanol (added to provide a reducing environment). Ferrochelatase (1 nmol/ml) was added last to start the reaction. Ferrochelatase activity from purified samples was expressed as nanomoles of heme per nanomole of ferrochelatase per minute.
Results
Expression and purification of homodimeric and heterodimeric ferrochelatases
Twelve human ferrochelatase EPP missense mutant (Q139L, Y191H, C236Y, F260L, S264L, M267I, M288K, P334L, K379N, H386P, C406S and F417S) expression vectors were constructed. When expressed as homodimers or heterodimers some mutants had decreased expression levels relative to wild type human ferrochelatase so for these six, 1L cultures were grown, harvested and processed to obtain sufficient protein.
Heterodimeric ferrochelatases were purified as described in Materials and Methods. The formation of the dimeric wild-type ferrochelatase (one His-tagged monomer + one CBPtagged monomer) and the heterodimeric mutant ferrochelatases (one normal CBP-tagged monomer + one mutated His-tagged monomer) was evaluated using western blot only.
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analysis. These analyses demonstrated that the heterodimeric ferrochelatase mutants H386P and M288K could not be isolated as pure proteins even though western blot analysis shows that both wild type and mutant proteins were expressed (data not shown).
All other mutants examined could be isolated as both homodimers and heterodimers.
Complementation of E. coli ∆hemH by F417S, C406S, H386P, M288K, and S264L
The ferrochelatase deficient E.coli strain (∆hemH) grows poorly in the absence of heme supplementation or complementation by a functional ferrochelatase 26 . The level enzyme activity necessary to complement these mutants is quite low and at the lower limit of in vitro detection in crude cell extracts. Plasmids carrying ferrochelatase cDNA with the EPP mutations that did not yield either measurable enzymatic activity or isolatable heterodimers were electroporated into ∆hemH cells to determine if any of these mutant ferrochelatases could restore a normal growth phenotype. The data from this experiment demonstrated that whereas the F417S and C406S mutant ferrochelatases complemented the ferrochelatase deficient ∆hemH E. coli, ferrochelatases with mutations at H386P, M288K, and S264L did not.
Dynamic light scattering
Dynamic light scattering (DLS) was performed on mutants that did not appear to possess a cluster. Data for the homodimeric mutant of C406S showed the presence of two different molecular sizes (data not shown). The first had a hydrodynamic radius of 4.09 nm, corresponding to a molecular weight of approximately 90 KDa and suggesting that the C406S ferrochelatase is still able to form a dimer in the absence of its [2Fe-2S]
clusters. However, the stability of the dimer is questionable. The second molecular size exhibited a hydrodynamic radius of 10.6 nm corresponding to a higher molecular weight only.
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Characterization of recombinant human ferrochelatases
To verify that the substitution of one or both His-tags on the wild type ferrochelatase by a CBP-tag did not have any effect on the characteristics of the wild type protein, the His/CBP-tagged, His/His-tagged and CBP/CBP-tagged wild type ferrochelatases were expressed, purified and characterized. All three forms of recombinant wild-type ferrochelatase (His/His-tag, CBP/CBP-tag and His/CBP-tag) had the same characteristic spectra (data not shown). Kinetic analysis showed that the ferrochelatases had similar apparent K m s for iron and mesoporphyrin substrates (Table 1) although the V max of the wild-type heterodimer is approximately 25% lower than that of the homodimer wild type. This may be explained by the differences in the purification procedures. Ferrochelatase with both His and CBP tags was purified through a procedure involving four different columns and concentrated for approximately one hour before use in kinetic analysis. In contrast, the homodimeric wild type with His-tag on both subunits was purified through a single column and did not need to be concentrated (see Materials and Methods). The lack or diminished activity in some heterodimers for which the homodimers has significant activity, such as P334L, may reflect protein denaturation occurring during the longer isolation procedure for heterodimers. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From the mutations F417S, C406S, H386P or M288K lacked the characteristic spectra of the [2Fe-2S] cluster indicating that the clusters were not assembled or that they were assembled but were not stable during isolation. Similar results were obtained with the heterodimeric forms of these mutants except for F417S which exhibited a pale reddish color during purification, but precipitated as eluted from the last column.
The kinetic parameters of the wild type and mutant ferrochelatases for iron and mesoporphyrin are summarized in Table 1 . There was no detectable enzyme activity for the homo-or heterodimers of M288K, C406S, F417S or H386P and so these are not included on the table.
Discussion
Ferrochelatase is a membrane associated homodimeric enzyme that exists at the convergence of the porphyrin synthetic pathway and iron supply 1, 14, 27 . It has recently been demonstrated that the myosin-dependent transferrin-endosome movement is essential for the efficient utilization of transferrin-borne Fe for heme synthesis in erythroid cells 28 and has been suggested that iron delivery to ferrochelatase in the mitochondrion results from direct contact with iron-loaded frataxin 29 . In addition it has been proposed, based upon both kinetic and structural approaches, that ferrochelatase interacts at least transiently with protoporphyrinogen oxidase (PPO), the penultimate enzyme in the pathway 30, 31, 15 For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From to participate in a hydrogen bond with R164, but its physical characteristics will be altered. Y191H exhibits slightly diminished catalytic capabilities and there is no evidence for any cooperativity between subunits in the heterodimeric enzyme.
The data for S264L homo-and heterodimers appear consistent for an enzyme homodimer that has two distinct and independent active sites. S264 is adjacent to H263 which has been suggested to be key in catalysis as the pyrrole proton acceptor from the entering substrate porphyrin 1, 19, 27 . Substitution of the bulkier leucine side chain in S264L may cause sufficient distortion of the backbone structure and move the imidazole of H263 out of position. P334 is highly conserved and is located at the bottom of the active site. For the mutation P334L it might be anticipated that at least local structures are deranged due to the insertion of the aliphatic side chain and the altered backbone orientation resulting from the change from an imino acid to an amino acid.
One clear result from the data presented here is that mutations affecting the stability of the [2Fe-2S] cluster (C406S and F417S) or on the formation/stability of the dimer (M288K) exhibit these effects in both homo-and heterodimers. The EPP mutation M267I has previously been shown by our our group to impart a temperature sensitive phenotype on ferrochelatase 32 . Conditions employed in the current study favor this mutant protein's stability. When the M288K EPP mutation was first identified and expressed in vitro, the recombinant homodimeric mutant was reported to have a residual activity less than 19% of the wild type 18 . The residue M288, which is present in the dimer interface, is highly conserved among all eukaryotic ferrochelatases that are dimeric proteins. In our hands recombinant M288K human ferrochelatase was inactive when assayed in vitro and when expressed in vivo failed to complement the ferrochelatase only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From deficient ∆hemH E. coli strain. Dynamic light scattering (DLS) examination of the homodimeric mutant M288K revealed a highly polydisperse size distribution indicating that ferrochelatase with the mutation M288K was subject to aggregation. A recombinant heterodimeric mutant form of this enzyme could not be isolated using the technique described above. Since the M288K homodimer could be isolated with the more rapid single metal affinity column procedure we believe that the heterodimer may be formed in vivo, but is poorly stable.
Neither recombinant homodimeric and heterodimeric H386P ferrochelatases could be isolated. The human ferrochelatase tertiary structure 13 shows that this residue is For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From mutations has distinctly profound structural and kinetic implications may be of value for genetic counseling.
An interesting features of EPP is the usual lack of anemia and ringed sideroblasts 2, 3 (erythroblasts containing iron overloaded mitochondria) as is found with X-linked sideroblastic anemia 36 , another disease resulting from a defect in heme biosynthesis .
During differentiation of erythrocyte precursors iron uptake is induced to satisfy the need for chelation into protoporphyrin to form heme, but is also essential for translational upregulation of erythroid ALAS via an iron-responsive element 34, 35 . Interestingly in some EPP patients the disease is exacerbated by oral iron therapy 37, 38, 39 . In EPP the erythroid program functions normally except that diminished levels of ferrochelatase result in less than stoichiometric conversion of protoporphyrin to heme. Since anemia is generally not a feature of EPP it is clear that sufficient levels of heme are eventually synthesized.
There are several reports of sideroblastic anemia in patients with clinical EPP although not all patients had diminished ferrochelatase activity 40,41,42.43,44 . In one report of patients with decreased ferrochelatase activity, the nature of the defect was not reported 42 . However, it would be expected that for two patients with a reported chromosome 18 deletion the lowered activity results from the loss of one ferrochelatase allele since the gene is located on 18q21.3. This was shown for one patient with ringed sideroblasts and a chromosome 18 deletion 44 . As suggested by these authors it would be anticipated that the remaining allele is somehow defective since clinical EPP is generally observed only when ferrochelatase activity is ~25%. Based upon our own findings above and reported previously 45 , we would suggest that for the three sideroblastic anemia patients identified with EPP-like symptoms including decreased ferrochelatase activity, EPP active site mutant residues described in the current study are at positions P334 (carbons in green), Y191 (carbons in light grey), and S264 (carbons in yellow). All structure figures were generated with PyMOL 46 .
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